| 000 | 01686 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518053648.0 | ||
| 264 | 0 | _c20200611 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a2574-3805 | ||
| 024 | 7 |
_a10.1001/jamanetworkopen.2019.8890 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMincu, Raluca I | |
| 245 | 0 | 0 |
_aCardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. _h[electronic resource] |
| 260 |
_bJAMA network open _c08 2019 |
||
| 300 |
_ae198890 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Systematic Review | ||
| 650 | 0 | 4 |
_aAcrylonitrile _xanalogs & derivatives |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAniline Compounds _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins B-raf _xtherapeutic use |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMahabadi, Amir A | |
| 700 | 1 | _aMichel, Lars | |
| 700 | 1 | _aMrotzek, Simone M | |
| 700 | 1 | _aSchadendorf, Dirk | |
| 700 | 1 | _aRassaf, Tienush | |
| 700 | 1 | _aTotzeck, Matthias | |
| 773 | 0 |
_tJAMA network open _gvol. 2 _gno. 8 _gp. e198890 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1001/jamanetworkopen.2019.8890 _zAvailable from publisher's website |
| 999 |
_c29991015 _d29991015 |
||